Novel nucleoside-based antimalarial compounds.

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• The malaria parasite Plasmodium falciparum utilizes a distinct nucleotide salvage pathway, unlike the human host's de novo biosynthesis.
• Targeting this unique pathway presents a potential strategy for selective antimalarial drug development.

Purpose of the Study:

• To synthesize and evaluate novel 2-, 6-, and 5'-modified adenosine ribonucleosides as potential antimalarial agents.
• To design compounds that are selectively toxic to Plasmodium falciparum by interfering with its nucleotide salvage pathway, while sparing host cells.

Main Methods:

• Chemical synthesis of twenty-two modified adenosine ribonucleoside analogues.
• In vitro bioassays using the K1 strain of Plasmodium falciparum.
• Cytotoxicity assays using the L6 rat myoblast cell line to determine selectivity.

Main Results:

• The synthesized compounds demonstrated potent antimalarial activity, with half-maximal inhibitory concentration (IC50) values as low as 110 nM against P. falciparum.
• The most effective analogue exhibited a high selectivity index (>1000) against the L6 rat myoblast cell line, indicating minimal host cell toxicity.

Conclusions:

• Modified adenosine ribonucleosides can effectively target the Plasmodium falciparum nucleotide salvage pathway.
• The developed compounds represent promising leads for the development of novel, selective antimalarial drugs with a favorable safety profile.